ARWR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AR

Mkt Cap

$7.89B

Volume

1.57M

Next Earnings

November 24th

Loading chart

AR

ARWRArrowhead Research Corporation

ARWR

Pay with—

Available Balance0.00

AR

Mkt Cap

$7.90B

Volume

1.57M

Next Earnings

November 24th

Chart Financials Earnings News About Insider Filings

Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment OpportunitiesThe HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.GlobeNewswire Inc. · Sep 30, 2026

Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines ExpandThe global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.GlobeNewswire Inc. · Jul 15, 2026

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsightThe complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from major pharmaceutical companies are expected to expand treatment options across multiple indications including PNH, aHUS, CIDP, and IgAN.GlobeNewswire Inc. · Apr 30, 2026

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightThe IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.GlobeNewswire Inc. · Apr 29, 2026

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption WidensCRISPR Therapeutics reported strong Q4 2025 results with Casgevy gene therapy generating $116 million in annual revenue and 147 patient initiations, nearly tripling from 2024. The company is advancing its pipeline with in vivo liver editing programs and RNA-based candidates. Shares surged 8.81% on the positive clinical progress and expanding market access.Benzinga · Feb 13, 2026

Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsightThe idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.GlobeNewswire Inc. · Feb 9, 2026

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human TrialsArrowhead Pharmaceuticals reported positive interim Phase 1/2a trial results for its obesity drugs ARO-INHBE and ARO-ALK7, which use RNA interference to target fat storage pathways. ARO-INHBE doubled weight loss and tripled fat reductions when combined with Eli Lilly's tirzepatide, while ARO-ALK7 showed rapid visceral fat reductions. Both candidates were well-tolerated, and the stock surged 17.81% to a new 52-week high.Benzinga · Jan 6, 2026

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsightThe article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.GlobeNewswire Inc. · Jan 9, 2025

NetApp, Zoom Video And 2 Other Stocks Insiders Are SellingThe Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Zoom Video Communications The Trade: Zoom Video Communications, Inc. (NASDAQ: ZM) Director Santiago Subotovsky sold a total of 1,100 shares at an average price of $65.38. The insider received around $71,919 from selling those shares. What’s Happening: On March 26, Rosenblatt analyst Catharine Trebnick reiterated ...Benzinga · Apr 4, 2024

EQT, Genie Energy And Other Big Stocks Moving Lower On MondayU.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation (NYSE: EQT) fell sharply during Monday’s session after the company announced that it entered into a definitive merger agreement to acquire Equitrans Midstream. EQT shares fell 8.4% to $34.37 on Monday. Here are some other big stocks recording losses in today’s session. Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares tumbled 18.5% to $8.09. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event. MoneyLion Inc. (NYSE: ML) dipped 15% to $63.36. Genie Energy Ltd. ...Benzinga · Mar 11, 2024

to start trading

AR

ARWRArrowhead Research Corporation

ARWR

Pay with—

Available Balance0.00

Your PositionYou don't own any ARWR yet.

Related Tickers

Earnings